SELLAS Life Sciences Group Inc. (SLS) |
|
2.42 0.02 (0.83%)
|
09-29 10:39 |
|
Open: |
2.44 |
Pre. Close: |
2.4 |
|
High:
|
2.45 |
Low:
|
2.42 |
|
Volume:
|
17,175 |
Market Cap:
|
23M |
|
|
|
|
SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.533 - 2.547 |
2.547 - 2.56 |
|
Low:
|
2.368 - 2.383 |
2.383 - 2.397 |
|
Close:
|
2.378 - 2.403 |
2.403 - 2.425 |
|
Technical analysis |
as of: 2020-09-29 10:16:04 AM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 3.40 One year: 3.97 |
| Support: |
Support1: 2.20 Support2: 1.76 |
| Resistance: |
Resistance1: 2.91 Resistance2: 3.40 |
| Pivot: |
2.31 |
| Moving Average: |
MA(5): 2.45 MA(20): 2.22
MA(100): 2.93  MA(250): 3.35 |
| MACD: |
MACD(12,26): -0.01 Signal(9): -0.08 |
| Stochastic oscillator: |
%K(14,3): 60.46 %D(3): 61.85 |
| RSI: |
RSI(14): 51.54 |
| 52-week: |
High: 11.00 Low: 1.46 Change(%): -59.2 |
| Average Vol(K): |
3-Month: 22162 10-Days: 18739 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.SLS has closed below upper band by 35.5%. Bollinger Bands are 3.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Sun, 13 Sep 2020
SELLAS Life Sciences Group, Inc - Consensus Indicates Potential 310.3% Upside - DirectorsTalk Interviews
Wed, 09 Sep 2020
SELLAS Receives IMPD Approval from the French Regulatory Authority for its Pivotal Phase 3 REGAL Study of Galinpepimut-S in Patients with Acute Myeloid Leukemia - GlobeNewswire
Wed, 09 Sep 2020
SELLAS Life Sciences (SLS) Receives IMPD Approval from French Regulatory Authority for its Pivotal Phase 3 REGAL Study of Galinpepimut-S in Patients with AML - StreetInsider.com
Wed, 02 Sep 2020
Where Does Wall Street Think Sellas Life Sciences Group Inc (SLS) Stock Will Go? - InvestorsObserver
Thu, 13 Aug 2020
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2020 Financial Results - GlobeNewswire
Fri, 31 Jul 2020
SELLAS Life Sciences Announces $9.2 Million Private Placement Priced At-The-Market - GlobeNewswire
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
9 |
| Shares Float (M) |
8 |
|
% Held by Insiders
|
2.08 |
|
% Held by Institutions
|
14.53 |
|
Shares Short (K)
|
148 |
|
Shares Short P. Month (K)
|
197 |
Stock Financials |
|
EPS
|
-4.954 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
0.560 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-54.2 |
|
Return on Equity (ttm)
|
-222.8 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
|
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-18 |
|
Levered Free Cash Flow (M)
|
-12 |
Stock Valuations |
|
PE Ratio
|
-0.49 |
|
PEG Ratio
|
|
|
Price to Book value
|
4.38 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-1.27 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
